SIGN-UP NOW! Click to become a The VoiceAmerica Talk Member for Free!
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 15th 2018: Synthetic Biologics-Protecting and Preserving the Gut Microbiome

Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel disease (IBS). Synthetic Biologics is developing two lead microbiome-focused drugs poised for Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain common

Read more
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Dr Joseph Sliman, MD, MPH

Dr. Sliman, MD, MPH, is Chief Medical Officer and joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs.
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 01/04/2024 08:00 01/04/2024 09:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel disease (IBS). Synthetic Biologics is developing two lead microbiome-focused drugs poised for Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used IV beta-lactam antibiotics for the prevention of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance AMR, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel disease with constipation (IBS-C). VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
Facebook Twitter Linkedin Social Media
presspass-banner